Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.

Détails

ID Serval
serval:BIB_41AC89778070
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.
Périodique
European Journal of Gastroenterology and Hepatology
Auteur(s)
Juillerat P., Pittet V., Vader J.P., Burnand B., Gonvers J.J., de Saussure P., Mottet C., Seibold F., Rogler G., Sagmeister M., Felley C., Michetti P., Froehlich F.
Collaborateur(s)
Swiss IBD Cohort Study Group
Contributeur(s)
Ballabeni P., Bauerfeind P., Beglinger C., Begré S., Bengoa J., Binek J., Boller D., Borovicka J., Braegger C., Brun P., Burnand B., Camara R., Criblez D., de Saussure P., Degen L., Delarive J., Ehmann T., Engelmann M., El Wafa A., Felley C., Frei A., Frei R., Fried M., Froehlich F., Gallot-Lavallée S., Gerlach T., Geyer M., Girardin M., Goetze O., Haack H., Hediger S., Hengstler P., Heyland K., Janiak P., Juillerat P., Brondolo VK., Knoblauch C., Kullak-Ublick GA., Manz M., Meier R., Meyenberger C., Michetti P., Mottet C., Müller C., Müllhaupt B., Nicolet T., Nydegger A., Pache I., Piccoli F., Pilz J., Pittet V., Rentsch R., Rey JP., Rihs S., Rogler D., Rogler G., Sagmeister M., Sauter B., Schaub N., Schibli S., Schoepfer A., Seibold F., Spalinger J., Stadler P., Steuerwald M., Straumann A., Sulz M., Schäppi M., Tempia-Caliera M., Thorens£££Joël£££ J. , Vader JP., Vavricka S., Vögtlin J., Von Känel R., Wachter G., Wermuth J., Wiesel P.
ISSN
1473-5687 (Electronic)
ISSN-L
0954-691X
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
22
Numéro
11
Pages
1352-1357
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
OBJECTIVE: Antitumor necrosis factor a agents have significantly improved the management of Crohn's disease (CD), but not all patients benefit from this therapy. We used data from the Swiss Inflammatory Bowel Disease Cohort Study and predefined appropriateness criteria to examine the appropriateness of use of infliximab (IFX) in CD patients.
METHODS: EPACT II (European Panel on the Appropriateness of CD Therapy, 2007; www.epact.ch) appropriateness criteria have been developed using a formal explicit panel process combining evidence from the published literature and expert opinion. Questionnaires relating to EPACT II criteria were used at enrollment and follow-up of all Swiss Inflammatory Bowel Disease Cohort Study patients. A step-by-step analysis of all possible indications for IFX therapy in a given patient allowed identification of the most appropriate indication and final classification in a single appropriateness category (appropriate, uncertain, inappropriate).
RESULTS: Eight hundred and twenty-one CD patients were prospectively enrolled between November 2006 and March 2009. IFX was administered to 146 patients (18%) at enrollment and was most frequently used for complex fistulizing disease and for the maintenance of remission induced by biological therapy. IFX therapy was considered appropriate in 44%, uncertain in 44%, and inappropriate in 10% of patients.
CONCLUSION: In this cohort, 9 out of 10 indications for IFX therapy were clinically generally acceptable (appropriate or uncertain) according to EPACT II criteria. Uncertain indications resulted mainly from the current more liberal use of IFX in clinical practice as compared with the EPACT II criteria.
Mots-clé
Adolescent, Adult, Anti-Inflammatory Agents/therapeutic use, Antibodies, Monoclonal/therapeutic use, Crohn Disease/diagnosis, Crohn Disease/drug therapy, Female, Gastrointestinal Agents/therapeutic use, Guideline Adherence, Humans, Male, Patient Selection, Practice Guidelines as Topic, Predictive Value of Tests, Prospective Studies, Severity of Illness Index, Switzerland, Treatment Outcome, Young Adult
Pubmed
Web of science
Création de la notice
25/10/2010 13:22
Dernière modification de la notice
03/03/2018 16:34
Données d'usage